OceanFirst Financial Corp. And Flushing Financial Corporation Announce Receipt of All Requisite Regulatory and Shareholder Approvals to Complete Proposed Merger and Annual Meeting Date

Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA

Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation

Classover Named to TIME's America's Top EdTech Companies of 2026

DocGo to Announce First Quarter 2026 Results on Monday, May 11, 2026

Vision Marine Technologies Secures Conditional TSX Venture Exchange Listing Approval, Expanding Capital Markets Access for Its Marine Technology Platform

BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET

Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy

Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock

First Phosphate Provides Analytical Results for Infill Drill Program at Begin-Lamarche Property

One Capsule, Endless Glow--Radiant Skin Starts Within

Allot to Release First Quarter 2026 Results and Host Conference Call on May 12, 2026

HBT Financial, Inc. Announces First Quarter 2026 Financial Results

CMS (867.HK/8A8.SG) Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer® and Cosmofer®

Verizon’s Transformation Actions Deliver Growth & Profitability in 1Q26; Company Raises Adjusted EPS Guidance

Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis

Real to Acquire REMAX, Creating a Leading Technology-Enabled Global Real Estate Platform

Lakeland Financial Reports Record First Quarter Performance; Loan Growth of 5% and Revenue Growth of 9% Contribute to 32% Increase in Net Income to $26.5 Million

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

Valmont Industries, Inc. to Participate in Gabelli’s Omaha Value Investor Conference